

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



四环医药  
*SihuanPharm*

**Sihuan Pharmaceutical Holdings Group Ltd.**

**四環醫藥控股集團有限公司**

*(incorporated in Bermuda with limited liability)*

**(Stock Code: 0460)**

**VOLUNTARY ANNOUNCEMENT  
ABOUT ENTERING INTO THE DRUG COMMISSIONED  
MANUFACTURING AND SUPPLY AGREEMENT  
OF COVID-19 TREATMENT DRUG DEUREMIDEVIR  
HYDROBROMIDE TABLETS**

The board of directors (the “**Board**”) of Sihuan Pharmaceutical Holdings Group Ltd. (the “**Company**” or “**Sihuan Pharmaceutical**”, together with its subsidiaries, the “**Group**”) is pleased to announce that Jilin Sihuan Pharmaceutical Co., Ltd. (“**Jilin Sihuan**”), the subsidiary of the Group, and Shanghai Vinnerna Biosciences Co., Ltd. (上海旺實生物醫藥科技有限公司) (“**Vinnerna Biosciences**”) entered into an agreement in relation to the cooperation regarding the manufacturing and supply of Deuremidevir Hydrobromide Tablets (氫溴酸氈瑞米德韋片) (product code: VV116/JT001, trade name: MINDEWEI (民得維®), “**VV116**”), an oral nucleoside analog anti-SARS-CoV-2 Category 1 innovative drug. Both parties will work closely to promote related work in technology transfer and commissioned production of VV116.

VV116 is Deuremidevir Hydrobromide Tablets, a Category 1 innovative drug applied by Vinnerna Biosciences, a subsidiary controlled by Shanghai Junshi Biosciences Co., Ltd. (stock code: 1877.HK), and was conditionally approved by the National Medical Products Administration after urgent review and approval on 28 January 2023, for the treatment of adult patients with mild to moderate coronavirus disease 2019 (COVID-19).

Pursuant to the agreement entered into by both parties and relevant drug administration law, Jilin Sihuan, as the authorized manufacturing partner, will cooperate with Vinnerna Biosciences to carry out the technology transfer work including process optimization, quality method transfer, pilot scale-up, process verification, as well as commissioned manufacturing and registration approval application. At the same time, Jilin Sihuan, as the main authorized manufacturing partner of Vinnerna Biosciences, will give full play to its advantage to provide efficient, stable and high-capacity market supply and support services.

The signing of this product commissioned manufacturing and supply agreement has not only led to the establishment of a win-win strategic partnership between the two parties, but also demonstrated the recognition from the industry to the Group's high-efficiency and quality manufacturing capacity. On the basis of complementary advantages, mutual benefits and mutual development, the Group believes that both parties will further advance their business progress and meet the future development needs.

### **About Sihuan Pharmaceutical**

Founded in 2001 and listed on the Main Board of The Stock Exchange of Hong Kong Limited in 2010, Sihuan Pharmaceutical is an international medical aesthetic and biopharmaceutical company led and driven by innovation, with an independent and leading research and development technology platform, a rich global product pipeline, strong product registration capability, a full dosage form production platform with high efficiency and low cost and a mature and excellent sales system. Adhering to the overall strategic objective of "full promotion of a two-wheel drive strategy of its medical aesthetics and biopharmaceutical businesses", Sihuan Pharmaceutical endeavours to build itself into a leading medical aesthetics and biopharmaceutical company in China.

This announcement is being made by the Group on a voluntary basis to update the investing public on the Group's latest business development, and does not constitute, and is not intended to be, an advertisement regarding the use of any medicine, surgical appliance, treatment or orally consumed product.

By order of the Board  
**Sihuan Pharmaceutical Holdings Group Ltd.**  
**Dr. Che Fengsheng**  
*Chairman and Executive Director*

Hong Kong, 8 February 2023

*As at the date of this announcement, the executive directors of the Company are Dr. Che Fengsheng (Chairman), Dr. Guo Weicheng (Deputy Chairman and Chief Executive Officer), Dr. Zhang Jionglong, Ms. Chen Yanling and Ms. Miao Guili; and the independent non-executive directors of the Company are Mr. Patrick Sun, Mr. Tsang Wah Kwong and Dr. Zhu Xun.*